---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-034230"
form_type: "8-K"
ticker: null
cik: "0001061027"
company_name: "Viracta Therapeutics, Inc."
filed_at: "2024-03-20T23:59:59+00:00"
generated_at: "2026-06-04T11:15:28.642037+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Viracta CFO/COO Dan Chevallard resigns; Melody Burcar appointed interim CFO

## Summary
- Dan Chevallard resigns as CFO and COO effective March 20, 2024 to pursue other opportunities; no disagreement with company.
- Melody Burcar appointed interim principal financial officer and principal accounting officer; previously SVP of Finance.
- Burcar receives annual base salary of $340,000, target bonus of 35%, and stock option grant of 100,000 shares at $0.99/share.
- Chevallard enters consulting agreement at $375/hour for up to 8 hours/month for up to 6 months; options/RSUs continue vesting.

## SEC filing metadata
- accession: 0000950170-24-034230
- form_type: 8-K
- cik: 0001061027
- company_name: Viracta Therapeutics, Inc.
- filed_at: 2024-03-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061027/000095017024034230/0000950170-24-034230-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061027/000095017024034230/virx-20240315.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-034230
- JSON: https://secwatch.observer/filing/0000950170-24-034230.json
- Plain text: https://secwatch.observer/filing/0000950170-24-034230.txt

## Key facts
- Executive change
  Dan Chevallard resigned as Chief Financial Officer and Chief Operating Officer at Viracta Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Financial Officer and Chief Operating Officer
  source text: On March 15, 2024, Dan Chevallard informed Viracta Therapeutics, Inc. (the “Company”) that he was resigning from his positions as Chief Financial Officer and Chief Operating Officer of the Company, effective on March 20, 2024, to pursue other opportunities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1061027/000095017024034230/0000950170-24-034230-index.htm
- Executive change
  Melody Burcar changed role as Senior Vice President of Finance at Viracta Therapeutics, Inc..
  - Action: promoted
  - Role: Senior Vice President of Finance
  source text: Melody Burcar, MBA, CPA, 41, was promoted to the Company’s Senior Vice President of Finance, effective March 18, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1061027/000095017024034230/0000950170-24-034230-index.htm
- Executive change
  Melody Burcar was appointed as interim principal financial officer and interim principal accounting officer at Viracta Therapeutics, Inc..
  - Action: appointed
  - Role: interim principal financial officer and interim principal accounting officer
  source text: Effective upon Mr. Chevallard’s resignation as Chief Financial Officer and Chief Operating Officer, Melody Burcar, the Company’s Senior Vice President of Finance, will serve as the Company’s interim principal financial officer and interim principal accounting officer while the Company engages in a search for a permanent replacement for Mr. Chevallard.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1061027/000095017024034230/0000950170-24-034230-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.